Nuvectis Pharma (NVCT) Common Equity (2021 - 2026)

Nuvectis Pharma has disclosed Common Equity across 6 years of filings, most recently posting $14.2 million for Q1 2026.

• Common Equity for Q1 2026 came in at $14.2 million, down 32.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.2 million (down 32.14% YoY), and the FY2025 annual result was $18.4 million, up 89.57% from the prior year.
• Common Equity came in at $14.2 million for Q1 2026 at Nuvectis Pharma, down from $18.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $24.0 million in Q3 2025 to a low of $9.7 million in Q4 2024.
• The 5-year median for Common Equity is $14.2 million (2026), against an average of $15.5 million.
• Across the five-year window, Common Equity jumped 44218.18% in 2022 and tumbled 38.38% in 2024, its largest moves.
• Nuvectis Pharma's Common Equity stood at $14.2 million in 2022, then fell by 14.19% to $12.2 million in 2023, then retreated by 20.39% to $9.7 million in 2024, then soared by 89.57% to $18.4 million in 2025, then fell by 22.77% to $14.2 million in 2026.
• The last three Common Equity figures came in at $14.2 million (Q1 2026), $18.4 million (Q4 2025), and $24.0 million (Q3 2025), per Business Quant data.